Pre-made Tislelizumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-581
Pre-Made Tislelizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tislelizumab (BGB-A317) is a humanized monoclonal antibody directed against PD-1. It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
---|---|---|---|---|
GMP-Bios-ab-581-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size: 1mg | 10mg | 100mg
Description
Products Name (INN Index) | Pre-Made Tislelizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
INN Name | Tislelizumab |
Target | PDCD1/PD-1 |
Format | Whole mAb |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | IgG4 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Approved |
Est. Status | Active |
100% SI Structure | 7bxa:BC:HL |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2017 |
Year Recommended | 2018 |
Companies | BeiGene;Celgene Corporation |
Conditions Approved | Hodgkin's disease;Urogenital cancer |
Conditions Active | Gastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Solid tumours;Ovarian cancer;Renal cancer |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<